The American Psychoanalytic Association presents
A Virtual Discussion with Robin Carhart-Harris, Ph.D. on Psychoanalysis and Psychedelics.
Hosted by Donald Moss, M.D.
April 15, 2023
11:30 a.m. - 1:30 p.m. Eastern Time
CLICK HERE TO REGISTER
Psychedelic therapy is anticipated to receive its first federal approval in 2024 and at least one U.S. State will begin issuing licenses to psychedelic therapy service providers in 2023. What do these developments mean for psychoanalytic psychotherapy? Could they catalyze or validate psychoanalytic processes and treatment? Does psychedelic therapy threaten the traditional psychoanalyst, or does it present an opportunity for psychoanalysis to modernize?
This symposium will address these topics and more in a timely dialogue with Professor Robin Carhart-Harris and Dr. Donald Moss, followed by audience Q+A.
Professor Carhart-Harris is Director of the new Psychedelics Division within the translational neuroscience center, Neuroscape, at the University of California, San Francisco.
Dr. Donald Moss is the Chair of the American Psychoanalytic Association’s Program Committee.
Fee structures vary depending on APsA membership and candidacy status. We offer discounted student rates. APsA is committed to expanding the accessibility of psychoanalytic programming. If registration cost presents a barrier to entry, please contact email@example.com and we will accommodate your needs.
For more information and to register, visit our website: www.apsameeting.org
This program will offer 2 Continuing Education Credits.
STATEMENT OF OBJECTIVES
The scientific sessions of the American Psychoanalytic Association’s meetings are intended to bridge the practice gaps in the professional knowledge of attendees by exploring new and recent developments in research, theory, technique, clinical knowledge and by offering opportunities to review essential psychoanalytic knowledge.
After attending the Psychoanalysis and Psychedelics Symposium, attendees should be able to:
1) Describe how psychedelic drugs work on the mind.
2) Discuss how the effect of psychedelic drugs might enhance psychoanalytic treatments.
CONTINUING PROFESSIONAL EDUCATION CREDITS
Physicians The American Psychoanalytic Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The American Psychoanalytic Association designates this Live Activity for a maximum of 2 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Psychologists The American Psychoanalytic Association is approved by the American Psychological Association to sponsor continuing education for psychologists. The American Psychoanalytic Association maintains responsibility for this program and its content.
Social Workers This activity is pending approval from the National Association of Social Workers.
New York State Social Workers American Psychoanalytic Association, Inc. is recognized by the New York State Education Department’s State Board for Social Work as an approved provider of continuing education for licensed social workers #SW-0186.
New York State Licensed Psychoanalysts American Psychoanalytic Association, Inc. is recognized by the New York State Education Department’s State Board for Mental Health Practitioners as an approved provider of continuing education for licensed psychoanalysts. #P-0013.
IMPORTANT DISCLOSURE INFORMATION FOR ALL LEARNERS: None of the planners and
presenters for this educational activity have relevant financial relationship(s)* to disclose with ineligible companies* whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients.
*Financial relationships are relevant if the educational content an individual can control is related to the business lines or products of the ineligible company.
-Updated December 2022
Contact us: firstname.lastname@example.org